UDENYCA® is administered in-office to ensure patient confidence

Next-day dosing with a prefilled syringe administered by a healthcare professional

UDENYCA® has been administered to over 200,000 patients since launch.*1

Dosing &
  • Do not administer UDENYCA® between 14 days before and 24 hours after administration of cytotoxic chemotherapy
  • The UDENYCA® prefilled syringe is not designed to allow for direct administration of doses less than 0.6 mL (6 mg), as the syringe does not bear graduation marks
  • Direct administration to pediatric patients weighing less than 45 kg, requiring dosing of less than 0.6 mL (6 mg), is not recommended due to the potential for dosing errors. For more information, please refer to the Full Prescribing Information


UDENYCA® PFS: Administered once per cycle

Single-dose prefilled subcutaneous injection of 6 mg administered once per chemotherapy cycle

dosing syringe

NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) suggest pegfilgrastim use to support clinical outcomes during chemotherapy.†3

See the guidelines

Receive occasional emails to learn more about UDENYCA®, reimbursement, and support services for your chemotherapy patients.

Sign up now

*January 2019 through December 2020.

Other suggestions for therapy are included in the NCCN Guidelines®.

References: 1. Data on file. Coherus BioSciences, Inc.; 2023. 2. UDENYCA® (pegfilgrastim-cbqv) Prescribing Information. Redwood City, CA: Coherus BioSciences, Inc.; 2023. 3. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Hematopoietic Growth Factors V.1.2022. © National Comprehensive Cancer Network, Inc. 2022. All rights reserved. Accessed April 27, 2023. To view the most recent and complete version of the guidelines, go online to NCCN.org. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.